# Kyverna Therapeutics, Inc.: overview KYTX · Nasdaq · CIK 1994702 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kytx.md) · [Financials](/companies/kytx/financials.md) · [Filings](/companies/kytx/filings.md) · [Insiders](/companies/kytx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.80)](/filings/0001193125-25-277584.md) | not reported | [(1.03)](/filings/0001193125-26-219397.md) | [(0.97)](/filings/0001193125-26-344607.md) | [(0.85)](/filings/0001193125-25-277584.md) | not reported | [(0.66)](/filings/0001193125-26-219397.md) | [(0.63)](/filings/0001193125-26-344607.md) | | Free cash flow | $m | [(27.6) d](/filings/0001193125-25-277584.md) | [(37.6) d](/filings/0001193125-26-126242.md) | [(44.9)](/filings/0001193125-26-219397.md) | [(32.0) d](/filings/0001193125-26-344607.md) | [(43.3) d](/filings/0001193125-25-277584.md) | [(33.5) d](/filings/0001193125-26-126242.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(89.61)](/filings/0000950170-25-046074.md) | [(3.33)](/filings/0001193125-26-126242.md) | [(3.64)](/filings/0001193125-26-126242.md) | | Free cash flow | $m | [(53.0)](/filings/0000950170-25-046074.md) | [(116)](/filings/0001193125-26-126242.md) | [(154)](/filings/0001193125-26-126242.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kytx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GordonMD Global Investments LP](/funds/2039349.md) | 2026-06-30 | $37.8m | 4,244,818 | | Unchanged | | [GILEAD SCIENCES, INC.](/funds/882095.md) | 2026-06-30 | $36.8m | 4,126,119 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $27.9m | 3,134,807 | | Added +2,257,729 | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $25.7m | 2,885,000 | | Reduced −225,000 | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $24.9m | 2,795,797 | | Added +795,797 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $17.8m | 2,000,000 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.9m | 1,897,451 | | Added +114,109 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $9.4m | 1,049,430 | | Added +625,604 | | [Insight Holdings Group, LLC](/funds/1305473.md) | 2026-06-30 | $8.8m | 989,054 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $8.8m | 982,307 | | Added +5,018 | ## Recent filings [All 182 filings](/companies/kytx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-24 | 10:00 ET | [8-K](/filings/0001193125-26-400062.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-400062 | | 2026-08-11 | 20:07 ET | [10-Q](/filings/0001193125-26-344607.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344607 | | 2026-08-11 | 20:04 ET | [8-K](/filings/0001193125-26-344572.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344572 | | 2026-07-27 | 12:00 ET | [8-K](/filings/0001193125-26-316916.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-316916 | | 2026-07-09 | 10:00 ET | [8-K](/filings/0001193125-26-298979.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-298979 | | 2026-06-02 | 20:30 ET | [8-K](/filings/0001193125-26-253604.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-253604 | | 2026-05-18 | 12:00 ET | [8-K](/filings/0001193125-26-227920.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-227920 | | 2026-05-12 | 20:08 ET | [10-Q](/filings/0001193125-26-219397.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219397 | | 2026-05-12 | 20:05 ET | [8-K](/filings/0001193125-26-219377.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219377 | | 2026-05-04 | 12:00 ET | [8-K](/filings/0001193125-26-202610.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-202610 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-126242.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1994702 - Tickers: KYTX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.